Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
Revive Therapeutics (OTCQB: RVVTF) has been approached by a prominent U.S. University Cancer Institute researcher to investigate Bucillamine's potential in cancer treatment, specifically for enhancing anti-tumor effects in advanced solid tumors. The research would be supported by NIH and other government funding.
The investigation builds on existing partnerships, including one with Defence R&D Canada – Suffield Research Centre, which is evaluating Bucillamine for nerve agent exposure treatment. The cancer research focuses on Bucillamine's role as a thiol donor that could neutralize reactive oxygen species and replenish reduced glutathione in the tumor microenvironment (TME), potentially amplifying antitumor effects.
This approach aims to address challenges in nucleic acid-based therapies, particularly regarding drug delivery and stability in the TME, which is characterized by low oxygen levels and elevated reduced glutathione.
Revive Therapeutics (OTCQB: RVVTF) è stata contattata da un importante ricercatore di un Istituto Universitario Statunitense di Oncologia per indagare sul potenziale della Bucillamina nel trattamento del cancro, in particolare per migliorare gli effetti antitumorali nei tumori solidi avanzati. La ricerca sarà supportata dal NIH e da altri finanziamenti governativi.
L'indagine si basa su partnership esistenti, inclusa una con Defence R&D Canada – Suffield Research Centre, che sta valutando la Bucillamina per il trattamento dell'esposizione agli agenti nervini. La ricerca sul cancro si concentra sul ruolo della Bucillamina come donatore di tioli, che potrebbe neutralizzare le specie reattive dell'ossigeno e ripristinare il glutatione ridotto nell'ambiente microtumorale (TME), potenzialmente amplificando gli effetti antitumorali.
Questo approccio mira a affrontare le sfide delle terapie basate sugli acidi nucleici, in particolare riguardo alla somministrazione del farmaco e alla stabilità nel TME, caratterizzato da bassi livelli di ossigeno e elevato glutatione ridotto.
Revive Therapeutics (OTCQB: RVVTF) ha sido contactada por un destacado investigador de un Instituto de Cáncer Universitario de EE. UU. para investigar el potencial de la Bucillamina en el tratamiento del cáncer, específicamente para mejorar los efectos antitumorales en tumores sólidos avanzados. La investigación contará con el apoyo del NIH y otros fondos gubernamentales.
La investigación se basa en asociaciones existentes, incluida una con Defence R&D Canada – Suffield Research Centre, que está evaluando la Bucillamina para el tratamiento de la exposición a agentes nerviosos. La investigación sobre el cáncer se centra en el papel de la Bucillamina como donante de tioles, que podría neutralizar las especies reactivas de oxígeno y reponer el glutatión reducido en el microambiente tumoral (TME), potencialmente amplificando los efectos antitumorales.
Este enfoque tiene como objetivo abordar los desafíos de las terapias basadas en ácidos nucleicos, particularmente en lo que respecta a la entrega y estabilidad del fármaco en el TME, que se caracteriza por bajos niveles de oxígeno y un elevado glutatión reducido.
Revive Therapeutics (OTCQB: RVVTF)는 미국의 저명한 대학 암 연구소 연구자로부터 암 치료에서 부실라민의 잠재력을 조사하라는 요청을 받았습니다. 특히 진행된 고형 종양에서 항종양 효과를 강화하는 데 초점을 맞추고 있습니다. 이 연구는 NIH 및 기타 정부 자금의 지원을 받을 것입니다.
조사는 Defence R&D Canada – Suffield Research Centre와의 기존 파트너십을 기반으로 하며, 여기서는 신경 작용제 노출 치료를 위해 부실라민을 평가하고 있습니다. 암 연구는 부실라민이 티올 기부자로서 반응성 산소종을 중화하고 종양 미세 환경(TME)에서 환원된 글루타티온을 보충할 수 있는 역할에 초점을 맞추고 있으며, 이는 잠재적으로 항종양 효과를 증대시킬 수 있습니다.
이 접근법은 특히 TME에서의 약물 전달 및 안정성에 관한 문제를 해결하는 것을 목표로 하며, TME는 낮은 산소 수준과 높은 환원 글루타티온으로 특징지워집니다.
Revive Therapeutics (OTCQB: RVVTF) a été contacté par un chercheur éminent d'un institut universitaire américain de cancérologie pour étudier le potentiel de la Bucillamine dans le traitement du cancer, en particulier pour améliorer les effets antitumoraux dans les tumeurs solides avancées. La recherche sera soutenue par les NIH et d'autres financements gouvernementaux.
L'enquête s'appuie sur des partenariats existants, y compris un avec Defence R&D Canada – Suffield Research Centre, qui évalue la Bucillamine pour le traitement de l'exposition aux agents neurotoxiques. La recherche sur le cancer se concentre sur le rôle de la Bucillamine en tant que donneur de thiols qui pourrait neutraliser les espèces réactives de l'oxygène et reconstituer le glutathion réduit dans le microenvironnement tumoral (TME), amplifiant potentiellement les effets antitumoraux.
Cette approche vise à relever les défis des thérapies basées sur les acides nucléiques, en particulier en ce qui concerne la délivrance et la stabilité des médicaments dans le TME, caractérisé par de faibles niveaux d'oxygène et un glutathion réduit élevé.
Revive Therapeutics (OTCQB: RVVTF) wurde von einem prominenten Forscher des US-amerikanischen Universitätskrebsinstituts kontaktiert, um das Potenzial von Bucillamin in der Krebsbehandlung zu untersuchen, insbesondere zur Verbesserung der antitumoralen Effekte bei fortgeschrittenen soliden Tumoren. Die Forschung wird durch NIH und andere staatliche Mittel unterstützt.
Die Untersuchung baut auf bestehenden Partnerschaften auf, einschließlich einer mit Defence R&D Canada – Suffield Research Centre, das Bucillamin zur Behandlung von Nervengift-Exposition bewertet. Die Krebsforschung konzentriert sich auf die Rolle von Bucillamin als Thiolspender, der reaktive Sauerstoffspezies neutralisieren und das reduzierte Glutathion im Tumormikroenvironment (TME) wieder auffüllen könnte, was potenziell die antitumoralen Effekte verstärken könnte.
Dieser Ansatz zielt darauf ab, Herausforderungen bei nucleinsäurebasierten Therapien anzugehen, insbesondere in Bezug auf die Medikamentenverabreichung und Stabilität im TME, das durch niedrige Sauerstoffwerte und erhöhtes reduziertes Glutathion gekennzeichnet ist.
- New potential application for Bucillamine in cancer treatment expanding market opportunities
- Partnership with prominent U.S. University Cancer Institute researcher
- Research to be funded by NIH and other government entities, reducing company expenses
- Building on existing partnership with Defence R&D Canada, showing multiple potential applications
- Research is still in early exploratory phase with no guaranteed outcomes
- No timeline provided for research completion or potential commercialization
- Multiple obstacles exist in drug delivery and stability for solid tumor treatments
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announced today that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment, particularly for boosting anti-tumor effects in patients with advanced solid tumors. This evaluation of Bucillamine in solid tumors would be integrated into a broader study, supported by funding from the NIH and/or other government entities. This proposed research builds on our strategy of evaluating novel uses of Bucillamine in academic and government supporting studies, including the partnership with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence, evaluating Bucillamine as a potential treatment for nerve agent exposure. Results from this study are expected shortly.
Rationale of Bucillamine in Cancer
Numerous nucleic acid-based therapies are under development for treating patients with advanced solid tumors. The high death rates linked to these cancers, both in the United States and worldwide, underscore the urgent need for better treatment options. Delivering external nucleic acid-based agents into the tumor microenvironment (“TME”) offers a promising approach to achieving targeted and powerful anti-tumor effects. The TME is marked by low oxygen levels and elevated reduced glutathione, which can destabilize drugs through nanoparticle breakdown in acidic or oxygen-deprived conditions. Additionally, various obstacles hinder both viral and non-viral delivery methods from effectively reaching the TME and releasing their therapeutic cargo. Adjusting the TME’s permeability or retention properties has been proposed as a way to boost the uptake of nucleic acid drugs given systemically, and the influence of these factors on patient outcomes in solid tumor cases remains a key focus of research.1 It is suggested that Bucillamine, a potential non-toxic supplement to certain solid tumor treatments, could act as a thiol donor to neutralize reactive oxygen species, replenish the reduced glutathione in the TME, and thereby amplify antitumor effects, presenting a potential application for this compound.
Michael Frank, CEO of Revive, commented: “We look forward to collaborating with a top U.S. cancer institute to investigate Bucillamine’s potential for solid tumors, confirming its anti-inflammatory and antioxidant effects, since inflammation and oxidative stress are recognized contributors to cancer initiation and growth.”
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “suggested”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three months ended September 30, 2024 ("MD&A"), dated November 29, 2024, which is available on the Company's profile at www.sedarplus.ca.
Source:
- Huayamares SG, Loughrey D, Kim H, Dahlman JE, Sorscher EJ. Nucleic acid-based drugs for patients with solid tumours. Nat Rev Clin Oncol. 2024 Jun;21(6):407-427. doi: 10.1038/s41571-024-00883-1. Epub 2024 Apr 8. PMID: 38589512.
FAQ
What is the new potential application for Bucillamine being investigated by Revive Therapeutics (RVVTF)?
How does Bucillamine (RVVTF) potentially work in cancer treatment?
What partnerships is Revive Therapeutics (RVVTF) currently involved in for Bucillamine research?
What funding sources will support RVVTF's Bucillamine cancer research?
